Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

Early Phase 1

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04420975Phase 1Active Not Recruiting

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Role: collaborator

NCT06422936Phase 2Active Not Recruiting

Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)

Role: lead

NCT04570332Phase 2Completed

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

Role: lead

NCT04508140Phase 2Terminated

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

Role: lead

NCT02828098Phase 1Completed

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Role: lead

NCT04777708Early Phase 1Terminated

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Role: collaborator

NCT05265650Phase 1Unknown

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

Role: collaborator

All 7 trials loaded